一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:PD-L1 Expression in Ampullary Adenocarcinoma.
PD-L1 Expression in Ampullary Adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在壶腹腺癌的背景下,本研究强调了 PD-L1 IHC 克隆 E1L3N 在不同阈值下观察到的阳性表达,其中在 10% 临界值时的关联尤为显著。
壶腹腺癌是一种罕见的肿瘤,通常采用复杂的Whipple手术进行治疗。若干组织学因素可预测不良预后,包括胰胆管形态、存在淋巴血管侵犯、神经周围侵犯以及局部或远处转移。以吉西他滨、5-氟尿嘧啶方案进行的全身治疗获益不一。免疫治疗检查点抑制剂已在多种癌中显示出有益的抗肿瘤效果,其中最显著的是在非小细胞肺癌中。这些新型药物的给药基于免疫组织化学表达(其可能指示也可能不指示对治疗的反应),以及多学科团队的细致决策。免疫组织化学(IHC)是展示免疫标志物的有效手段,并已在多种肿瘤类型中用于预测和预后目的。
PD-L1 IHC(克隆号E1L3N)应用于101例壶腹腺癌。同时评估了TIL(肿瘤浸润淋巴细胞)。对免疫反应性进行评估,并按以下染色阈值分类:肿瘤细胞(膜和/或细胞质染色模式)为<1%、<5%、<10%和≥10%,免疫细胞为5%和10%临界值。
我们发现,在10%的截断值下,73.3%(74/101)的患者为男性(P = .006),年龄大于50岁(P < .001),肿瘤大小<3 cm(P = .001)。这与肠分化(P = .004)和1级肿瘤(P = .001)显著相关。12例患者也出现了复发(P = .03)。
PD-L1 IHC (clone E1L3N) was applied in 101 cases of ampullary adenocarcinoma. Tumor infiltrating lymphocytes were also evaluated. The immunoreactivity was assessed and categorized into following staining thresholds: <1%, <5%, <10% and ≥10% for tumor cells (membranous and/or cytoplasmic staining pattern), and 5% and 10% cut-offs for immune cells.
We found that at a 10% cut-off, 73.3% (74/101) patients were men ( P = .006) older than 50 years of age ( P < .001) presenting with a tumor measuring <3 cm ( P = .001). It was significantly associated with intestinal differentiation ( P = .004) and grade 1 tumors ( P = .001). Twelve patients presented with recurrence as well ( P = .03).
In the context of ampullary adenocarcinoma, this study highlights the positivity observed with the PD-L1 IHC clone E1L3N at different thresholds, with the particularly stronger associations being evident at a 10% cut-off.
MEMBER ACCOUNT
登录成功会直接打开下一页。